Prognostic impact of K-RAS mutational status and primary tumor location in patients undergoing resection for colorectal cancer liver metastases: an update

• Published in: Future oncology (London, England) Vol. 15; no. 27; pp. 3149 - 3157
• Main Authors: O Connor, Juan M, Sanchez Loria, Fernando, Ardiles, Victoria, Grondona, Jorge, Sanchez, Pablo, Andriani, Oscar, Fauda, Martin, Brancato, Fernando, Huertas, Eduardo, Alvarez, Fernando, de Santibañes, Eduardo
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.09.2019
• Subjects: Adult; Aged; Argentinian group; Biological products; Biomarkers, Tumor; Cancer therapies; Chemotherapy; Colorectal cancer; Colorectal Neoplasms - genetics; Colorectal Neoplasms - mortality; Colorectal Neoplasms - pathology; Combined Modality Therapy; Female; Humans; KRAS • liver metastases; Liver; Liver Neoplasms - mortality; Liver Neoplasms - secondary; Liver Neoplasms - surgery; liver resection; Male; Metastasis; Middle Aged; molecular profiling; multidisciplinary; Mutation; Neoplasm Staging; Patients; perioperative chemotherapy; Prognosis; Proto-Oncogene Proteins p21(ras) - genetics; reference centres; Surgery; Survival Analysis; Variables; liver resection; KRAS • liver metastases; multidisciplinary; perioperative chemotherapy; reference centres; Argentinian group; chemotherapy; molecular profiling
• ISSN: 1479-6694; 1744-8301
• DOI: 10.2217/fon-2019-0196

To determine the impact of KRAS mutation status on survival in patients undergoing surgery for colorectal liver metastases (CLM). Patients with resected CLM and KRAS mutations. Survival was compared between mt-KRAS and wt-KRAS. Of 662 patients, 174 (26.3%) were mt-KRAS and 488 (73.7%) wt-KRAS. mt-KRAS patients had significantly lower recurrence-free survival (HR: 1.42; 95% CI: 1.10–1.84). There were no differences between the groups for sidedness. Poorer survival was associated with mt-KRAS with positive lymph nodes, >1 metastases, tumors >5 cm, synchronous tumors and R1–R2. KRAS mutation status can help predict recurrence-free survival. Primary tumor location was not a prognostic factor after resection. KRAS mutation status can help design a multidisciplinary approach after curative resection of CLM.